In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

A handful of small, early-stage clinical trials are investigating whether CAR-T therapy can improve symptoms in multiple ...

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

In this interview, Sagar Lonial, MD, discussed the EXCALIBER-RRMM trial design and the potential role of iberdomide in the ...

Triple-negative breast cancer is one of the most aggressive and difficult forms of breast cancer to treat. Unlike many other types of breast cancer, it does not have the common hormone receptors that ...

Every year, thousands of people are blinded suddenly, like Durst, by injuries to their cornea, the dome-shaped lenses that cap each iris. These injuries are often debilitating. In the weeks after his ...

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

A “living drug” was developed as a cancer treatment. Now it is showing promise for conditions, such as lupus and multiple sclerosis, that have long been considered incurable.

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell ...